Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and
fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of
desloratadine compared to fexofenadine following single and multiple oral doses administered
to desloratadine slow metabolizers.